SANTHERA PHARMACEUTICALS HOLDING AG - FY 2025 Results

Santhera Pharmaceuticals Holding AG delivered a strong FY2025 investor update, reporting revenue growth to CHF 77.2 million, ahead of guidance, supported by accelerating AGAMREE uptake, expanding reimbursement access and partner market momentum. Product sales rose 72%, driven by Germany, Austria and the UK, while Catalyst generated US sales of $117 million and China partner Sperogenix advanced its self-pay launch. European growth remains central to Santhera’s strategy, with Spain and Italy launches expected to support 2026 revenue guidance of CHF 80–90 million and cash flow breakeven targeted for Q3 2026. The Guardian long-term study strengthened AGAMREE’s differentiation, showing comparable efficacy to traditional corticosteroids with improved safety, reduced fracture risk and maintained growth. Management also highlighted global expansion through Nexera in Japan, Korea, Australia and New Zealand, high-margin distributor agreements, manufacturing scale-up, and potential rare disease asset acquisitions to leverage Santhera’s commercial infrastructure.